Skip to main content

Sjogren-Larsson Syndrome

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Aldeyra Therapeutics
Aldeyra TherapeuticsMA - Lexington
1 program
1
ADX-102 1% Topical Dermal CreamPhase 31 trial
Active Trials
NCT03445650Completed11Est. Jan 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Aldeyra TherapeuticsADX-102 1% Topical Dermal Cream

Clinical Trials (1)

Total enrollment: 11 patients across 1 trials

NCT03445650Aldeyra TherapeuticsADX-102 1% Topical Dermal Cream

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Start: Jul 2018Est. completion: Jan 202011 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.